Innate Pharma reports Phase 1 data for Nectin-4 ADC IPH4502
Dose-escalation study shows manageable tolerability and early antitumor activity, including in patients previously treated with enfortumab vedotin.
Innate Pharma SA presented initial Phase 1 data for IPH4502, its investigational Nectin-4-targeting antibody-drug conjugate carrying an exatecan payload, on November 18, 2026 at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026). The company announced initial Phase 1 data from its ongoing study of IPH4502 in patients with advanced solid tumors.1
The dose-escalation study enrolled 76 patients with advanced solid tumors across six dose levels ranging from 0.6 mg/kg to 3.6 mg/kg given once every three weeks, with patients heavily pretreated at a median of 3.5 prior lines of therapy, including 19 patients with urothelial cancer who had all previously received PADCEV (enfortumab vedotin).1
As of an August 17, 2026 data cutoff, IPH4502 was described as well-tolerated with low overall hematologic toxicity, and the maximum tolerated dose was set at 3.6 mg/kg every three weeks, with stomatitis as the only dose-limiting toxicity and no febrile neutropenia, hematologic dose-limiting toxicities, or signal of peripheral neuropathy.1 Grade 3 or higher treatment-emergent adverse events occurred in 43.4% of patients, including Grade 3 or higher anemia in 11.8%, while stomatitis occurred in 27.6% overall, with 3.9% Grade 3 or higher.1
On antitumor activity, at the maximum tolerated dose of 3.6 mg/kg, an objective response rate of 33% (2/6) was observed in non-urothelial tumors.1 Among the 19 urothelial cancer patients, most enrolled at 2.4 or 2.8 mg/kg, with 4 at 3.2 mg/kg and none at the 3.6 mg/kg MTD; at these intermediate doses, 3 partial responses occurred and the unconfirmed disease control rate was 68.4% (95% CI 46.0-84.6).1
Looking ahead, the company is initiating Phase 1 dose optimization in second-line or later urothelial cancer following enfortumab vedotin, with the first patient planned in the first half of 2027, testing split dosing on Days 1 and 8 of each cycle with mandatory prophylaxis to reduce stomatitis.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.